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Hyperactivation of NF-B via the MEK signaling is
indispensable for the inhibitory effect of cAMP
on DNA damage-induced cell death
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Abstract
With cAMP signaling having a profound inhibitory effect on DNA damage-induced apoptosis in B-cell precursor
acute lymphoblastic leukemia (BCP-ALL) cells, understanding how this signaling pathway affects the survival
capacity of the cell has important implications for cancer therapy. We have recently shown that p53 is critical for
the inhibitory effect of cAMP on genotoxic agents-mediated apoptosis in BCP-ALLs. Here, we show that elevation
of cAMP levels in cells exposed to DNA damage enhances the nuclear translocation and DNA binding of NF-B by
accelerating the phosphorylation of IKKb and thereby phosphorylation and degradation of IBa. Furthermore, we
show that the ability of cAMP to potentiate the ionizing radiation-induced activation of NF-B requires the activity
of MEK. Importantly, pharmacological or genetic ablation of NF-B reversed the inhibitory effect of cAMP on DNA
damage-induced apoptosis, demonstrating that, in addition to p53, cAMP relies on the activity of NF-B to provide
cells with a survival advantage in the face of DNA damage. Collectively, our results uncover a novel and important
interaction between the cAMP and NF-B pathways that may have implications for the targeted treatment of
lymphoid malignancies, such as BCP-ALL, in which aberrant NF-B activity functions as a driving force for
treatment resistance.
Background
Activation of apoptosis in tumor cells is essential for the
ability of cancer therapeutic drugs, such as genotoxic
agents, to elicit a successful antineoplastic response [1,2].
Importantly, the apoptotic process in cancer cells is often
compromised, enabling these cells to resist the cytotoxic
effect of antitumor drugs and thus leading to the emer-
gence of drug-resistant malignancies [3-5]. The ability of
genotoxic agents to induce apoptosis in the target cancer
cells is primarily influenced by the activity of two key sig-
naling networks, the nuclear factor-B (NF-B) and p53
pathways [6,7]. NF-B is a dimeric transcription factor
that in the resting state is sequestered in the cytoplasm
through its association with one of the inhibitory B
(IB) proteins [8]. In response to DNA damage, the IB
kinase (IKK) complex phosphorylates IBa at S32 and
S36, an event that marks IBa for ubiquitination and
proteasomal degradation, thus allowing the NF-B
complex (p50/p65) to translocate to nucleus where it
binds DNA and regulates the expression of a variety of
genes, including antiapoptotic genes [7,9]. Consistent
with this prosurvival function of NF-B, inhibition of
NF-B activation has been shown to improve the apopto-
tic response of cells to cancer therapeutics [10]. Further-
more, the constitutive and deregulated activation of NF-
B found in many solid tumors as well as hematological
malignancies is believed to promote cell survival and
confer treatment resistance [9,11,12].
The transcription factor p53 is a tumor suppressor
protein that is stabilized and activated in response to
various types of cellular stress, including DNA damage
[13,14]. This results in transactivation of a number of
downstream genes whose products induce cell cycle
arrest or apoptosis depending on the cell type and the
nature of stress. For instance, lymphoid cells readily
undergo p53-dependent apoptosis in response to DNA
damage [15]. The inability to induce p53 or loss of nor-
mal p53 function is thought to facilitate cancer initiation
and progression and to increase the survival potential of
the cell in response to anticancer treatment.
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In contrast to most carcinomas, the incidence of p53
mutations in hematological malignancies is notably low
[16-18]. This indicates the involvement of other
mechanisms that impinge on p53 and prevent its apop-
tosis-inducing effect. Based on our results in a recent
study [19], we proposed cAMP signaling to be one such
mechanism. We showed that activation of cAMP signal-
ing in primary B-cell precursor acute lymphoblastic leu-
kemia (BCP-ALL) blasts as well as BCP-ALL-derived
cell lines inhibited the accumulation of p53 and pro-
tected the cells from DNA damage-induced apoptosis.
Given that the fate of cells exposed to DNA damage
depends on the balance between the NF-B-induced
prosurvival signal and the p53-activated proapoptotic
program [4], we wished to investigate whether NF-B,
in addition to p53, plays a role in the ability of cAMP to
diminish the apoptotic response of BCP-ALL cells to
DNA damage. Here, we show that cAMP potentiates
the induction of NF-B by DNA damage. Furthermore,
we show that attenuation of NF-B activity reverses the
inhibitory effect of cAMP on DNA damage-induced
apoptosis. Importantly, our results indicate a critical role
for MEK signaling in mediating the potentiating effect
of cAMP on DNA damage-induced NF-B activation.
Based on these results, we conclude that cAMP, through
inhibition of p53 accumulation and simultaneous poten-
tiation of NF-B activity, renders cells resistant to the
apoptosis-inducing effect of DNA damage. Thus, the
potential use of NF-B modulators may prove beneficial
in treatment of cancers in which aberrant activation of
cAMP signaling endows the cells with a prosurvival
advantage.
Results
Alleviation of NF-B activity reverses the inhibitory effect
of cAMP on IR-induced cell death
In our recent study, we showed that stimulation of
cAMP signaling inhibits DNA damage-induced accumu-
lation of p53 and apoptosis in BCP-ALL cells [19].
Given the observations that DNA damage, in addition
to induction of p53, also engages the prosurvival NF-B
pathway, we wished to examine whether NF-B plays a
role in cAMP-mediated inhibition of DNA damage-
induced cell death. To do so, we used the BCP-ALL
cell lines Reh and EU-3 and the lymphoblastoid cell
line TK6, all of which express wt p53, and examined
the inhibitory effect of cAMP signaling on DNA
damage-induced cell death in the presence of the NF-
B inhibitor Bay 11-7082. As previously demonstrated,
induction of cAMP levels by forskolin, an activator of
adenylyl cyclase, 8-CPT-cAMP, a membrane-permeable
analog of cAMP, or a combination of forskolin and the
phosphodiesterase inhibitor, IBMX, inhibited the IR-
induced cell death (Figure 1). Interestingly, whereas
treatment of cells with Bay 11-7082 had marginal effect
on cell death induced by IR alone, it markedly alle-
viated the inhibitory effect of cAMP-elevating agents on
IR-induced cell death in all three cell types. To further
confirm this observation, we performed siRNA-
mediated knockdown of the p65 subunit of NF-B in
Reh and TK6 cells and examined the effect of elevation
of cAMP levels on DNA damage-induced cell death. As
shown in Figure 2, knockdown of p65 by siRNA alle-
viated the inhibitory effect of cAMP-elevating agents on
IR-induced cell death in Reh and TK6 cells. Taken
together, these results indicate that NF-B is required
for the inhibitory effect of cAMP on DNA damage-
induced cell death.
Figure 1 Pharmacological attenuation of NF-B activity
alleviates the inhibitory effect of forskolin or 8-CPT-cAMP on
IR-induced cell death. Cells were cultured in the absence or
presence of 5 μM Bay 11-7082 alone (Reh and TK6) or together with
400 μM IBMX (EU-3) for 90 min before treatment with or without 80
μM forskolin (Reh and TK6), 100 μM forskolin (EU-3) or 200 μM 8-
CPT-cAMP for 30 min. Cells were then exposed to 10 Gy IR,
harvested after 12 h (EU-3) or 20 h (Reh and TK6) and analyzed for
PI uptake by FACS (n = 4). *p < .01, **p < .03 relative to cells
treated with IR only. The histograms in the right panel depict
percent inhibition of IR-induced cell death by forskolin, 8-CPT-cAMP
or forskolin and IBMX in the presence or absence of Bay 11-7082.
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cAMP enhances IR-induced phoshorylation and
degradation of IBa and subsequent activation of NF-B
Given the observation that inhibition of NF-B activity
reverses the cAMP-mediated inhibition of DNA damage-
induced cell death, we examined key events in the NF-B
pathway to assess whether this pathway is regulated in
response to elevation of cAMP levels. Induction of NF-
B activity typically requires the activity of the IB kinase
(IKK) complex, consisting of IKKa, IKKb kinases and the
scaffold protein IKKg/NEMO [8]. Upon phosphorylation
of the activation loops of IKKa (S176/S180) and IKKb
(S177/S181), the IKK complex is activated and phosphor-
ylates the NF-B-bound IB proteins, targeting them for
proteasomal degradation and thus allowing NF-B to
translocate to nucleus where it binds to NF-B target
promoters and regulates their target genes [20-24]. To
examine the effect of cAMP on the activity of IKK, Reh
cells were exposed to IR in the absence or presence of
forskolin, collected at regular intervals for a total of 8 h,
and analyzed by Western blotting with antibodies specific
for phosphorylated IKKa (S176/S181) and IKKb (S177/
S181). As shown in Figure 3A, exposure of cells to IR led
to phosphorylation of IKKa and IKKb within 2 h. By 4 h
after IR, phosphorylation of IKKa and IKKb declined
slightly and continued to decrease thereafter so that by 8
h postirradiation it had reached the basal levels found in
untreated cells. Interestingly, forskolin alone led to phos-
phorylation of IKKb. Furthermore, exposure of cells to IR
in the presence of forskolin potentiated the IR-induced
phosphorylation of IKKb. In both cases, the kinetics of
forskolin-induced phosphorylation of IKKb correlated
closely with phosphorylation of IKKb induced by IR
alone.
Having identified cAMP as an inducer of IKKb phos-
phorylation, we proceeded to examine the effect of
cAMP on phosphorylation and degradation of IBa. To
this end, Reh cells were treated with IR in the absence
or presence of forskolin, harvested at 2 and 4 h postirra-
diation and subjected to immunoblot analysis using an
anti-phospho-IBa antibody and an antibody recogniz-
ing nonphosphorylated IBa. In parallel with kinetics of
phosphorylation of IKKa and IKKb, phosphorylation
and degradation of IBa was induced by 2 h after expo-
sure of cells to IR before declining at 4 h postirradiation
(Figure 3B). Furthermore, exposure of cells to forskolin
potentiated the effect of IR on IBa phosphorylation
and degradation with similar kinetics. Interestingly,
although exposure of cells to forskolin alone increased
phosphorylation of IKKb, it failed to induce phosphory-
lation and degradation of IBa. The ability of forskolin
to potentiate the IR-induced phosphorylation-dependent
degradation of IBa suggested that forskolin would
enhance the IR-mediated nuclear accumulation of NF-
B. To examine this notion, Reh cells that were exposed
to IR in the absence or presence of forskolin were sub-
jected to subcellular fractionation and the nuclear frac-
tion was analyzed by immunoblotting with antibodies
against the p65 subunit of NF-B. As shown in Figure
3C, in conformity with kinetics of IBa degradation, the
expression of nuclear p65 was induced by 2 h after
exposure of cells to IR before declining slightly at 4 h
postirradiation. Notably, treatment of cells with forskolin
had a marked enhancing effect on the IR-induced
nuclear accumulation of p65 at both time points.
Next, we wished to examine whether the enhancing
effect of cAMP on IR-mediated activation of NF-B path-
way requires the activity of IKK kinase, the enzyme
responsible for phosphorylation of IBa and thus induc-
tion of NF-B. To this end, we examined the effect of
Bay 11-7082 on forskolin-mediated regulation of IR-
induced phosphorylation and degradation of IBa as well
as nuclear translocation of p65. Bay 11-7082 is an inhibi-
tor of IKK kinase and attenuates the phosphorylation and
subsequent degradation of the NF-B inhibitor, IBa. As
Figure 2 Knockdown of p65 relieves the inhibitory effect of
forskolin or 8-CPT-cAMP on IR-induced cell death. Cells
transfected with control siRNA or p65 siRNA were treated with or
without forskolin (80 μM) or 8-CPT-cAMP (200 μM) for 30 min
before exposure to IR (10 Gy). After 20 h, cells were analyzed for PI
uptake by FACS (n = 4). The p values were calculated relative to
cells treated with IR only: Reh, *p < .01, **p < .04. TK6, *p < .03, **p
< .05. The histograms in the right panel depict percent inhibition of
IR-induced cell death by forskolin or 8-CPT-cAMP in cells transfected
with control siRNA or p65 siRNA.
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expected, Bay 11-7082 inhibited the IR-induced phos-
phorylation and degradation of IBa, and thus attenuated
the translocation of p65 into the nucleus (Figure 3D).
Importantly, in cells exposed to IR in the presence of for-
skolin, Bay 11-7082 inhibited the phosphorylation and
degradation of IBa as well as the nuclear translocation
of p65 to levels similar to those found in cells that were
treated with only IR in the presence of Bay 11-7082.
Thus, the stimulatory effect of cAMP on IR-induced acti-
vation of NF-B pathway depends on IKK kinase activity.
To determine the potential enhancing effect of cAMP
on IR-induced NF-B DNA binding, we used an ELISA-
based assay to measure IR-mediated DNA binding in
the absence or presence of forskolin. Figure 4A shows
that exposure of Reh cells to IR led to a robust increase
in the amount of NF-B bound to the consensus site
oligonucleotides by 2 h. Thereafter, the NF-B DNA
binding activity decreased gradually so that by 6 h post-
IR it had reached to a level slightly above that found in
untreated cells. Importantly, exposure of cells to forsko-
lin significantly enhanced the IR-induced DNA binding
of NF-B at all time points.
Next, we wished to examine whether cAMP affected
the NF-B-dependent gene transcription. We transiently
transfected Reh cells with an NF-B-dependent lucifer-
ase reporter construct and examined them by luciferase
assay after exposure to IR in the presence or absence of
forskolin. As shown in Figure 4B, the NF-B luciferase
reporter activity was relatively low in untreated cells or
cells that were treated with forskolin alone. Exposure of
cells to IR increased the NF-B promoter activity 5 fold
within 2 h. The transcriptional activity of NF-B then
Figure 3 cAMP enahnaces the IR-induced phosphorylation of IKKb and nuclear translocation of p65. (A) Reh cells were treated with or
without forskolin (80 μM) for 30 min before irradiation (10 Gy). Cells were harvested at the indicated times and subjected to Western blot
analysis with the indicated antibodies. The figure shows 1 representative blot of 4 experiments. (B) Reh cells were treated as in A, harvested at
the indicated times and subjected to immunoblot analysis with the indicated antibodies. The figure shows 1 representative blot of 4
experiments. (C) Reh cells were treated as in A. One half of each sample was used for preparation of total cell lysate and the other half was
subjected to cellular fractionation to obtain nuclear lysate. The lysates were then analyzed by immunoblotting with the indicated antibodies. The
figure shows 1 representative experiment of 3. (D) Reh cells were cultured in the absence or presence of Bay 11-7082 (5 μM) for 90 min before
treatment with or without forskolin (80 μM) for 30 min. Cells were then exposed to 10 Gy IR and harvested after 2 h. One half of each sample
was used for preparation of total cell lysate and the other half was subjected to cellular fractionation to obtain nuclear lysate. The lysates were
then analyzed by immunoblotting with the indicated antibodies. The figure shows 1 representative experiment of 3.
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decreased gradually so that by 6 h after IR, it was
induced 4 fold compared to untreated cells. Notably,
pretreatment of cells with forskolin had a profound
potentiating effect on the IR-induced NF-B-dependent
transcription at all time points.
Two major downstream targets of cAMP are protein
kinase A (PKA) and exchange protein directly activated
by cAMP (Epac) [25-27]. To examine whether the
enhancing effect of cAMP on NF-B activity is mediated
through PKA or Epac, Reh cells that were transfected
with an NF-B-dependent luciferase reporter construct
were exposed to IR in the absence or presence of 8-
CPT-cAMP or 8-pCPT-2’-O-Me-cAMP and then exam-
ined for NF-B luciferase reporter activity. 8-CPT-
cAMP is an activator of both PKA and Epac, whereas 8-
pCPT-2’-O-Me-cAMP is a potent and specific agonist of
Epac with no effect on PKA activity [28]. As can be
seen in Figure 4C, pretreatment of Reh cells with 8-
Figure 4 Potentiation of NF-B DNA binding and transcriptional activity by cAMP. (A) Reh cells were treated with or without forskolin (80
μM) for 30 min before irradiation (10 Gy). Cells were harvested at the indicated times after IR and nuclear extracts were prepared. The binding
activity of p65 in the nuclear extracts was then determined by the p65 TransAM assay (n = 4). *p < .01, **p < .05 relative to cells treated with IR
only. (B) Reh cells were transfected with a plasmid encoding the luciferase gene under 3 repeats of a NF-B consensus binding site. After 24 h,
cells were cultured in the presence or absence of forskolin (80 μM) for 30 min before exposure to IR (10 Gy). At the indicated times after IR, cells
were harvested and the luciferase activity was measured as described in Materials and methods (n = 4). *P < .01 relative to cells treated with IR
only. (C) Reh cells were transfected as in B. After 24 h, cells were cultured in the presence or absence of forskolin (80 μM), 8-CPT-cAMP (200 μM)
or 8-pCPT-2’-O-Me-cAMP (400 μM) for 30 min before exposure to IR (10 Gy). Cells were harvested at 4 h after IR and luciferase activity was
measured as described in Materials and methods (n = 4). *P < .01, **P < .05 relative to cells treated with IR only. (D) Freshly isolated splenocytes
from 3 × B-luc transgenic mice were cultured in the presence or absence of forskolin (80 μM) for 30 min before exposure to IR (10 Gy). After 2
h, luciferase activity was measured as described in Materials and Methods. The boxes show the median, upper and lower quartile, and the
whiskers show the range of values (n = 9, *P < .05 by Wilcoxon signed rank test when compared with cells treated with IR only). The outlier
value (○) stems from one mouse.
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CPT-cAMP had a robust potentiating effect on IR-
induced NF-B activity. In contrast, exposure of cells to
a concentration of 8-pCPT-2’-O-Me-cAMP as high as
400 μM did not enhance the NF-B transcriptional
activity in IR-treated cells, indicating that cAMP
potentiates the IR-induced NF-B activity in a PKA-
dependent manner.
Finally, to confirm that the enhancing effect of cAMP
on the NF-B activity also occurs in normal cells, we
used splenocytes isolated from 3 × B-luc transgenic
mice [29], and examined them for luciferase activity
after exposure to IR in the absence or presence of for-
skolin. Similar to the results obtained with Reh cells,
treatment of splenocytes with IR led to an increase in
luciferase activity within 2 h (Figure 4D). Furthermore,
pretreatment of these cells with forskolin significantly
enhanced the IR-induced NF-B activity.
MEK signaling is required for cAMP-mediated activation
of NF-B
The involvement of ATM in activation of NF-B follow-
ing DNA damage raises the possibility that cAMP, by
enhancing the activity of ATM, could potentiate the IR-
induced activation of NF-B. However, our finding that
cAMP does not affect the activity of ATM after DNA
damage argues against this notion [19]. Therefore, to
assess the mechanism underlying the potentiating effect
of cAMP on IR-mediated activation of NF-B, we direc-
ted our attention to molecular events downstream of
ATM. The MEK signaling is coupled to NF-B in a
number of stress-induced responses [30,31]. Further-
more, the MEK pathway has been reported to be acti-
vated in an ATM-dependant manner and induce the
activity of IKK, thereby leading to activation of NF-B
[32,33]. Therefore, we chose to investigate the potential
role of this pathway in mediating the enhancing effect
of cAMP on NF-B activation and cell survival. First,
we determined the effects of MEK inhibition on the
ability of cAMP to inhibit the DNA damage-induced
cell death. Treatment of Reh, TK6 or EU-3 cells with
the MEK inhibitor PD 98059 alone did not have an
appreciable effect on IR-induced cell death (Figure 5A).
Notably, pretreatment of cells with PD 98059 attenuated
the inhibitory effect of elevated levels of cAMP on IR-
induced cell death in all three cell types. To further con-
firm this result, we transfected Reh cells with siRNAs
directed against MEK1 and MEK2 and examined them
for cell death following exposure to IR in the absence or
presence of forskolin. As shown in Figure 5B, whereas
disruption of MEK1 and MEK2 genes expression did
not inhibit the IR-induced cell death, it alleviated the
ability of forskolin to attenuate cell death induced by IR.
Next, we wished to examine the effect of MEK1 and
MEK2 inhibition on the ability of cAMP to enhance the
IR-mediated induction of IKK phosphorylation. To do
so, Reh cells that were treated with PD 98059 were
exposed to IR in the absence or presence of forskolin
and harvested at 2 h postirradiation for examination of
MEK1 and MEK2 phosphorylation by Western blotting.
Whereas treatment of cells with PD 98059 had a slight
inhibitory effect on IKKb phosphorylation induced by IR
alone, it profoundly attenuated the enhancing effect of
forskolin on IR-induced phosphorylation of IKKb
(Figure 6A). Importantly, enhancement of IKKb phos-
phorylation by forskolin in IR-treated cells correlated
with potentiation of ERK2 phosphorylation. Because
ERKs are predominant downstream targets of MEK [34],
this result suggests the notion that cAMP enhances the
activity of MEK.
To assess the role of MEK signaling in cAMP-
mediated enhancement of NF-B activity following
DNA damage, MEK activity in Reh cells that were trans-
fected with an NF-B-dependent luciferase reporter
construct was inhibited by either treatment of cells with
PD 98059 or by RNA interference. Cells were then
examined by luciferase assay after exposure to IR in the
presence or absence of forskolin. As shown in Figure
6B, whereas disruption of MEK signaling with either PD
98059 or MEK1 and MEK2 siRNAs slightly decreased
the IR-induced NF-B promoter activity, it substantially
inhibited the potentiating effect of cAMP on IR-
mediated NF-B-dependent transcription.
Finally, to rule out the possibility that the reversal of
the inhibitory effect of cAMP on IR-induced cell death
through attenuation of MEK1 and MEK2 or NF-B
activities may be due to stabilization of p53, we exam-
ined the expression of p53 in cells that were treated
with PD 98059 or Bay 11-7082. As shown in Figure 6C,
pretreatment of Reh cells with PD 98059 or Bay 11-
7082 had no effect on the basal level of p53 protein.
The inability of Bay 11-7082 to increase the level of p53
is in contrast with previous studies showing that IKKb
decreases the stability of p53 protein [35,36]. Further-
more, inhibition of MEK1 and MEK2 or NF-B did not
affect the ability of forskolin to attenuate the IR-
mediated accumulation of p53. Collectively, these results
indicate that MEK-NF-B signaling axis plays an impor-
tant p53-independent role in the inhibitory effect of
cAMP on DNA damage-induced cell death.
cAMP induces the expression of survivin in IR-treated
cells in an NF-B-dependent manner
To address the mechanism by which cAMP-induced
hyperactivation of NF-B mediates the inhibitory effect
of cAMP on DNA damage-induced cell death, we pro-
ceeded to examine the expression of a number of NF-
B-regulated antiapoptotic proteins, such as Bcl-xL, c-
IAP1, MCL-1, XIAP and survivin [37]. To this end, Reh
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cells that were treated with or without Bay 11-7082
were exposed to IR in the absence or presence of for-
skolin and harvested at 12 h postirradiation for exami-
nation of by Western blotting. Exposure of cells to IR
alone or to IR in the presence of forskolin had no effect
on the expression of Bcl-xL, c-IAP1, MCL-1 or XIAP
(data not shown). Interestingly, whereas exposure of Reh
cells to IR slightly reduced the level of survivin, pretreat-
ment of cells with forskolin substantially induced the
expression of survivin (Figure 7). Notably, this effect of
forskolin was attenuated by treatment of cells with Bay
11-7082, indicating that cAMP-induced expression of
survivin in DNA-damaged cells is mediated by NF-B.
Given the ability of survivin to inhibit cell death [38],
these results suggest that at least one of the mechanisms
by which NF-B mediates the inhibitory effect of cAMP
on DNA damage-induced cells death is through its
capacity to induce the expression of survivin.
Discussion
Stress signals, such as DNA damage, activate both the
proapoptotic p53 and the prosurvival NF-B pathways
[7,6]. Thus, cell fate after DNA damage is determined
by the outcome of the competition between these two
antagonistic signaling pathways [4]. Therefore, it is not
surprising that tumor cells utilize mechanisms to block
Figure 5 Inhibition of MEK signaling alleviates the inhibitory effect of cAMP on IR-induced cell death. (A) Cells were cultured in the
absence or presence of 50 μM PD 98059 alone (Reh and TK6) or together with 400 μM IBMX (EU-3) for 45 min before treatment with or
without 80 μM forskolin (Reh), 200 μM 8-CPT-cAMP (TK6) or 100 μM forskolin (EU-3) for 30 min. Cells were then exposed to 10 Gy IR, harvested
after 12 h (EU-3) or 20 h (Reh and TK6) and analyzed for PI uptake by FACS (n = 4). The p values were calculated relative to cells treated with IR
only: Reh, *p < .02. TK6, *p < .01, **p < .03. EU-3, *p < .01, **p < .04. The histograms in the right panel depict percent inhibition of IR-induced
cell death by forskolin, 8-CPT-cAMP or forskolin and IBMX in the presence or absence of PD 98059. (B) Reh cells were transfected with control
siRNA or siRNAs against MEK1 and MEK2. Cells were then treated with or without forskolin (80 μM) for 30 min before exposure to IR (10 Gy).
After 20 h, cells were analyzed for PI uptake by FACS (n = 4). *p < .01, **P < .03 relative to cells treated with IR only. The histogram in the right
panel depicts percent inhibition of IR-induced cell death by forskolin in cells transfected with control siRNA or MEK1 and MEK2 siRNAs.
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p53 induction and induce NF-B activation in order to
avoid genotoxic-mediated killing. We believe that
cAMP signaling represents such a mechanism. In this
study we have identified NF-B as a target of cAMP
signaling in cellular response to DNA damage. We
report that activation of the cAMP signal transduction
pathway enhances the DNA damage-induced phos-
phorylation and activation of IKKb, thereby facilitating
the IKK-mediated phosphorylation and degradation of
IkBa, an event that augments the activity of NF-B in
cells afflicted with DNA damage. Based on these find-
ings together with our previous result demonstrating
the inhibitory effect of cAMP on p53 accumulation
[19], we propose a model in which activation of cAMP
signaling in B cells exerts a protective effect against
DNA damage-induced apoptosis by simultaneously
downregulating the proaoptotic p53 protein and
enhancing the activity of the prosurvival NF-B pro-
tein (Figure 8). The ability of cAMP to affect both of
these two antagonistic signaling pathways in order to
endow the cell with a survival advantage may be of
particular importance in tumors that retain wt p53. It
may be suggested that acquisition of maximal protec-
tion against DNA damage in such tumors requires not
only abrogation of the p53 function but also induction
of the NF-B activity.
Figure 6 MEK signaling is required for cAMP to affect the IR-induced NF-B activation. (A) Reh cells were cultured in the presence or
absence of 50 μM PD 98059 for 45 min before treatment with or without forskolin (80 μM) for 30 min. cells were then exposed to IR (10 Gy),
harvested at 2 h postirradiation and subjected to immunoblot analysis with the indicated antibodies. The figure shows 1 representative blot of 3
experiments. (B) Reh cells were transfected with a plasmid encoding the luciferase gene under 3 repeats of a NF-B consensus binding site or
left untreated. After 24 h, cells were treated as in A, harvested at 4 h postirradiation and analyzed for luciferase activity as described in Materials
and methods (n = 4). *p < .02 relative to cells treated with IR only. (C) Reh cells were cultured in the absence or presence of 5 μM Bay 11-7082
for 90 min or 50 μM PD 98059 for 45 min before treatment with or without forskolin (80 μM) for 30 min. Cells were then exposed to IR (10 Gy),
harvested after 4 h and subjected to Western blot analysis with the indicated antibodies. The figure shows 1 representative blot of 3
experiments.
Figure 7 cAMP-induced expression of survivin in IR-treated
cells. Reh cells were cultured in the absence or presence of 5 μM
Bay 11-7082 for 90 min before treatment with or without forskolin
(80 μM) for 30 min. Cells were then exposed to IR (10 Gy),
harvested after 12 h and subjected to Western blot analysis with
the indicated antibodies. The figure shows 1 representative blot of 3
experiments.
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In line with our finding that the cAMP-mediated inhi-
bition of DNA damage-induced cell death depends on
the ability of cAMP to hyperactivate NF-B, during the
final phase of the preparation of this manuscript, Safa et
al. reported that elevation of cAMP in doxorubicin-
exposed Nalm-6 cells induced the activity of NF-B
[39]. Furthermore, these authors showed that NF-B
activity contributes to the ability of cAMP to inhibit cell
death in doxorubicin-treated Nalm-6 cells. However, in
contrast to our findings showing that elevation of cAMP
in DNA-damaged Reh cells induces the expression of
survivin without affecting the levels of Bcl-2 or XIAP
(for Bcl-2 see [19]), Safa et al. showed that cAMP
increases the expression of Bcl-2 and XIAP in doxorubi-
cin-treated Nalm-6 cells.
Given the importance of NF-B activity in oncogen-
esis as well as its contribution to suppression of the
apoptotic potential in cancer therapy [9,12,40], we also
examined the mechanism by which cAMP signaling
enhances the DNA damage-induced NF-B activation.
Inactive NF-B dimers are sequestered in the cytoplasm
in association with IB proteins [8]. Following DNA
damage, activated ATM interacts with NEMO in the
nucleus and the resulting ATM/NEMO complex trans-
locates to cytoplasm where it activates IKK complex,
leading to phosphorylation and subsequent degradation
of IBa [7]. This event facilitates translocation of NF-
B into nucleus where it binds DNA and activates an
antiapoptotic transcriptional program. Our observation
that forskolin enhances the DNA damage-induced phos-
phorylation and degradation of IBa indicated that
cAMP positively regulates the IKK complex to induce
NF-B activation. This conclusion was further sup-
ported by the finding that inhibition of IKK activity by
Bay 11-7082 alleviated the potentiating effect of cAMP
on IBa phosphorylation and degradation. cAMP could
enhance the activity of NF-B by modulating the ATM-
NEMO axis. However, the inability of cAMP to affect
the DNA damage-induced activation of ATM [19] sug-
gested that cAMP enhanced NF-B activity through an
alternative mechanism. The finding that abrogation of
MEK activity abolishes the ability of cAMP to potentiate
the DNA damage-induced activity of NF-B indicates
that MEK signaling functions in such capacity. Impor-
tantly, disruption of MEK signaling had no appreciable
effect on the activity of NF-B in cells that were
exposed to IR alone. This observation is in contradiction
with the results of Panta et al [33] showing that inhibi-
tion of MEK results in downregulation of doxorubicin-
or IR-mediated activation of NF-B. Whereas the cells
utilized by Panta et al were mainly of fibroblast origin,
we have exclusively used cells of B lymphocyte lineage.
Therefore, this discrepancy may be explained by the
suggestion that the MEK pathway relays the DNA
damage signal to NF-B in a cell type-specific manner.
Notwithstanding, our results show that, at least in BCP-
ALL and lymphoblastoid cells, the MEK signaling
engages the NF-B pathway in DNA damaged cells only
when cAMP signaling is activated.
The mechanism by which cAMP activates MEK sig-
naling should also be addressed. It can be envisioned
that stimulation of MEK phosphorylation and activation
by cAMP can be achieved by (i) direct phosphorylation
of MEK by PKA, or (ii) positive regulation of an activat-
ing event upstream of MEK proteins. The finding that
MEK is not efficiently phosphorylated by PKA in vitro
[41] diminishes the possibility that in vivo PKA activates
MEK through direct phosphorylation. At present, we
favor the second possibility in which cAMP induces the
activity of a factor that is required for phosphorylation
and activation of MEK. This mechanism is supported by
the findings that cAMP stimulates MEK activity though
activation of B-RAF pathway [42].
Degradation of IBa and the resulting nuclear translo-
cation of NF-B and its binding to DNA are necessary
but insufficient events for the induction of an NF-B
response. Covalent modifications of key residues of NF-
Figure 8 Model depicting how cAMP potentiates the activation
of NF-B by DNA damage and modulates cell death.
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B are also crucial for its transcriptional activity down-
stream of IBa [43]. Furthermore, these modifications
are thought to determine the strength and duration of
the NF-B transcriptional response. For instance, indu-
cible phosphorylation of p65 on S276 by PKA has been
shown to promote its interaction with transcriptional
coactivators p300 and CBP and thus enable NF-B to
activate gene transcription [44-46]. In the absence of
antibodies specific for phosphorylated p65 on S276 [47],
we can only speculate that elevation of cAMP in cells
exposed to DNA-damaging agents most probably leads
to phosphorylation of p65 on S276, thus enhancing the
DNA damage-induced transcriptional activity of NF-B.
In such case, cAMP signaling would positively affect the
activity of NF-B at two levels: one involves enhance-
ment of DNA damage-induced phosphorylation and
degradation of IBa, an event that positively regulates
nuclear translocation of NF-B. At the second level,
cAMP, by amplifying the PKA-dependent phosphoryla-
tion of p65, stimulates the transcriptional activity of NF-
B.
Alterations in NF-B activity is recognized as key
pathological feature in various lymphoid malignancies
[12]. Indeed, aberrant activity of NF-B occurs in nearly
all childhood ALL tumors [48], an event suggested to
contribute to resistance of these cells to DNA damage.
The credentials of cAMP as an antiapoptotic factor in
BCP-ALL cells [19] and its ability to hyperactivate NF-
B lend further support to our notion that inhibitors of
cAMP signaling pathway might prove beneficial in treat-
ment of BCP-ALL tumors.
Material and methods
Reagents and antibodies
Forskolin and propidium iodide (PI) were obtained
from Sigma-Aldrich. PD 98059 was purchased from
Tocris Bioscience. Bay 11-7082 was obtained from Cal-
biochem. 8-CPT-cAMP and 8-pCPT-2’-O-Me-cAMP
were from BioLog. Luciferase Assay system was from
Promega. Antibodies against IBa (#9242), phospho-
IBa (S32; #2859), p65 (#3034), IKKa (#2682), IKKb
(#2684), phospho-IKKa/b (S176/S180; #2697), ERK1/2
(#9102), and phosphor-ERK1/2 (T202/Y204; #9101)
were from Cell Signaling Technology. Anti-actin
(H196) and anti-Lamin B1 (H-90) were obtained from
Santa Cruz Biotechnology.
Cell cultures, radiation treatment and cell death analysis
Reh [49], EU-3 and TK6 were cultured as previously
described [19]. For isolation of mice splenocytes, mice
were sacrificed by cervical dislocation and spleens were
removed and homogenized in a petri dish. Splenocytes
were washed and adjusted to 2 × 106 cells/ml in RPMI
supplemented with 10% heat-inactivated fetal bovine
serum (Life Technologies), 2 mM glutamine, 125 U/ml
penicillin, 125 μg/ml streptomycin (Gibco), and 50 μM
b-mercaptoethanol (Sigma-Aldrich) at 37 °C in a humi-
fied incubator with 5% CO2. For treatment of cells with
g-radiation, cells were exposed to a 137Cs source at a
dose rate of 4.3 Gy/min using a Gammacell irradiator
from MSD Nordion. To analyze cell death, cells were
incubated with PI (20 μg/ml) at room temperature for
10 min before examination for PI uptake by flow
cytometry.
Transfection and reporter gene assay
For siRNA transfection, Reh or TK6 cells (6 × 106) were
transfected with 16 pmol Signalsilence NF-B p65
siRNA (6261; Cell signaling Technology) or stealth
RNAi for human MEK1 and MEK2 (12935-025; Invitro-
gen) using the nucleofection solution R and the O-17
program (Reh) or solution V and the X-05 program
(TK6) with a nucleofector device (Amaxa Biosciences).
SignalSilence Control siRNA (6201; Cell Signaling tech-
nology) or control siRNA (12935-300; invitrogen) were
used as controls for p65 and MEK1/2 siRNAs, respec-
tively. Cells were then incubated for 24 h before further
treatment. For reporter gene assay, Reh cells were
cotransfected with 8 μg B-luciferase plasmid and 4 μg
b-galactosidase expression vector. 20 h after transfec-
tion, cells were subjected to further treatment. To pre-
pare lysates, 100 μl reporter lysis buffer (Promega) was
added to each sample, and the supernatant was collected
after centrifugation at 13,000 rpm for 2 min. Aliquots of
cell lysates (20 μl) containing equal amounts of protein
(20-30 μg) were placed into wells of an opaque black
96-well microplate. An equal volume of luciferase sub-
strate was added to all samples, and luminescence was
measured in a microplate luminometer. The value of
luciferase activity was normalized to transfection effi-
ciency monitored by the co-transfected b-galactosidase
expression vector.
NF-B DNA Binding Assays
Nuclear protein binding to a consensus NF-B oligonu-
cleotide was determined using an enzyme-linked immu-
nosorbent assay-based kit (TransAm p65, Active Motif).
Absorbance was read at 450 nm.
Subcellular fractionation
Reh cells were resuspended in buffer A (10 mM Tris-
HCl [pH 7.5], 10 mM NaCl, 3 mM MgCl2, 0.1 mM
PMSF, 1 mM DTT. NP-40 (0.05%) was added, and the
cells were incubated for 20 min on ice. The lysates
were centrifuged for 5 min at 200 × g at 4 °C, and the
supernatant collected (cytosolic fraction). The nuclear
fraction was obtained by sonication of the pellet in
buffer A.
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Immunoblot analysis
For immunoblot analysis, cells were lysed in radioimmu-
noprecipitation buffer (RIPA; 50 mM Tris-HCl [pH 7.4],
150 mM NaCl, 1% NP-40, 50 mM NaF, 10 mM b-gly-
cerophosphate, 0.1% SDS, 0.5% EDTA, 1 mM Na3VO4,
0.2 mM PMSF, 10 μg/ml leupeptin, 0.5% aprotinin).
Equal amounts of protein were separated on a 7.5% (for
IKKa/b) and 10% (for other proteins) SDS-PAGE. After
transfer to a nitrocellulose membrane (GE Healthcare),
proteins were detected using appropriate primary anti-
bodies and the enhanced chemiluminescence detection
system (ECL Plus, Amersham Biosciences).
Statistical analysis
SPSS 14.0.2 for Windows was used to perform statistical
analysis. The paired sample t test was used to test signif-
icance in cell line experiments, whereas the Wilcoxon
signed-rank test was applied to experiments with mice
splenocytes. Specific cell death was calculated using the
following equation: (% experimental cell death in the
ionizing (IR)-treated sample - % spontaneous cell death
in the absence of IR)/(100% - % spontaneous cell death
in the absence of IR) × 100. In all figures, histograms
show mean values of the indicated number of experi-
ments with error bars corresponding to SEM values.
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